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Abstract
Background and Aim: Intentional weight loss, primarily by improving insulin resistance, is known to decrease the need for
anti-diabetic medications. In this study, we assess the magnitude of weight loss that resulted in dose reductions or
discontinuation of anti-diabetic medications in overweight or obese patients with type 2 diabetes (DM) undergoing weight
loss treatment.
Methods: Case records of 50 overweight or obese patients with DM who successfully decreased dosage or discontinued
diabetes medications after losing weight via attendance at two University-based, outpatient weight management centers
were analyzed. Follow-up visits, weight reduction interventions, and decisions for dose reductions or discontinuation of
medications were individualized to patient needs by the treating physician.
Results: Mean starting BMI was 35 kg/m2, mean age 53.4 years, and 58% were male. All 50 used at least one anti-diabetic
medication (30 metformin, 39 sulfonylureas, 31 insulin, 21 sitagliptin) to manage blood sugar. Mean duration of follow-up
was 30.2 months. Mean weight loss was 10.864.1 kgs (11.1% of initial body weight 64.7%). 22/50 patients (44%)
discontinued anti-diabetes medications (14 sulfonylureas [36%], 7 insulin [23%], 4 sitagliptin [19%]). The mean percentage
weight loss achieved at the point of successful discontinuation of medication was 11.2%63.5% (14% for sulphonylureas,
11% for insulin, and 7.1% for sitagliptin). Mean percentage weight loss of 5.6%62.8% (5.1% for sulphonylureas, 4.3% for
insulin, and 7.1% for sitagliptin) was required for initial dose reduction. For every 5% weight loss, predicted dose reductions
were sulphonylureas, 39%; insulin, 42%; and any anti-diabetic medications, 49%.
Conclusion: Among overweight or obese patients with type 2 diabetes, intentional weight loss of 7–14% was typically
required for full discontinuation of at least one anti-diabetic medication. Discontinuation of insulin was achieved at a mean
weight reduction of 11% of initial body weight.
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Introduction

compared to those with normal BMI (BMI 18.5–25) [3]. Further, on
average, obese individuals with DM have a higher prevalence of
end-organ damage and are at higher risk for cause-specific mortality
compared to obese individuals without DM [4,5]. Obesity and DM
in unison also generate immense health care costs [6,7].
DM in obese patients is predominantly related to insulin
resistance; thus, intentional weight loss, by improving insulin
resistance, decreases the risk of incident diabetes, and in patients
with existing diabetes results in better glycemic control [8,9]. The
quantitative association between improvement in glycemia with
weight loss and dose reductions or discontinuation of anti-diabetic
medications is not well studied. This association would be clinically
useful in treating, counseling and motivating patients in their
weight loss efforts.

National survey data for 2007–2008 indicate that 33.8% of US
adults are obese [body mass index (BMI; calculated as weight in
kilograms divided by height in meters squared)$30], and the
combined prevalence of overweight and obesity is reported to be
68% [1]. Obesity and overweight are associated with numerous
medical problems such as hypertension, type 2 diabetes, coronary
artery disease, dyslipidemia, gallbladder disease, sleep apnea,
osteoarthritis, and hyperuricemia [2,3].
Type 2 diabetes mellitus (DM) in obese patients is a particularly
important condition. Data from the Behavioral Risk Factor
Surveillance System showed that overweight (BMI 25–29.9), obese
(BMI 30–39.9), and morbidly obese (BMI$40) US adults had 1.59,
3.44 and 7.37 times higher odds, respectively, of diagnosed DM,
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aerobic exercise and strength training. Follow-up visit frequency
was variable, but typically involved weekly group support sessions
and/or individual follow-up visits with a physician. Duration of
treatment was also individualized, and in this sample ranged from
6 months to 3 years. The decision to alter the dose of or
discontinue medications for weight-sensitive conditions was based
upon the clinical judgment of the treating physician, taking into
account relevant markers of control of the underlying condition
(e.g., symptoms and signs, fingerstick and fasting blood glucose
measurement, HbA1c). The biochemical and symptomatic
response to medication regimen changes were monitored to
ensure that modifications were neither premature nor unduly
delayed.

In this study of overweight and obese patients from two
University-based weight management clinics, we studied the
association between the percentage of weight loss and dose
reductions or discontinuation of anti-diabetic medications.

Materials and Methods
Ethics statement
The study was approved by the Institutional Review Board of
Johns Hopkins Bloomberg School of Public Health. Informed
consent was not obtained from the study participants because the
data was analyzed anonymously and was in accordance with
Institutional Review Board guidelines. The Institutional Review
Board verified the anonymity of data analysis performed in this
study.

Outcome determination
The primary outcome of interest was discontinuation of any of
the anti-diabetic medications. Other outcomes assessed were
reduction in dose of anti-diabetic medications, mean and
percentage weight loss at study exit, mean and percentage weight
loss at the time of discontinuation of anti-diabetic medications,
mean time to discontinuation of anti-diabetic medications, mean
time to first dose reduction of anti-diabetic medications, mean and
percentage weight loss at the time of first dose reduction of antidiabetic medications, and average numbers of dose reductions for
each of the anti-diabetic medications.

Study setting and design
In this retrospective cohort study, case records of patients with
BMI.25 kg/m2 at the time of enrollment into two specialty outpatient weight management centers, the Johns Hopkins Weight
Management Center in Baltimore, MD and the George
Washington Weight Management Program in Washington, DC
were analyzed. Both were convenience samples. Patients were
sampled if they enrolled in these centers during the period March
2008 to August 2010, had at least 6 months of follow-up data,
reported taking anti-diabetic medications at the time of initial
enrollment, and had at least one documented reduction in dosage
or discontinuation of a prescribed anti-diabetic medication before
the study concluded in March 2011. Exclusion criteria included:
less than 6 months of follow-up, absence of dose reduction or
discontinuation of anti-diabetic medication, no diagnosis of
diabetes, prior surgical treatment of obesity, obesity associated
with named syndromes, drug-induced obesity, endocrine causes of
obesity, type 1 DM, pregnant and lactating women, and those
with symptomatic coronary artery disease, chronic kidney disease,
severe pulmonary artery hypertension, or physical limitations that
prevented adherence to the prescribed physical activity.

Cohort summary
The study cohort was open with respect to entry and exit. The
time origin for the study was entry or enrollment into the weight
management program. The time metric was months of follow-up.
Patients exited the cohort if they developed the primary outcome
of interest or were administratively censored at study conclusion
(in March 2011).

Statistical analysis
Baseline characteristics of the study cohort and excluded
patients were expressed in number (%) for categorical variables,
and as mean 6 standard deviation for continuous variables.
Continuous and categorical variables were compared between the
study cohort and the excluded patients using student’s t test and
chi-squared test as appropriate. The study cohort was further
categorized into 3 BMI categories (overweight: BMI 25–29.99 kg/
m2, obese: BMI: 30–39.99 kg/m2, morbidly obese: BMI$40 kg/
m2) at baseline as per standard guidelines [12]. Continuous and
categorical variables were compared at baseline and at study
conclusion between the three BMI categories using one-way
analysis of variance and chi-square test, as appropriate. The
changes in variables at study conclusion were compared with their
baseline values for the entire cohort and within each of the three
BMI categories using paired t-tests. At study conclusion, follow-up
time was calculated in person-months for the total cohort and the
three BMI categories. Missing data were imputed using multiple
imputations with the previous observation carried forward [13].
Mean and percentage weight loss achieved at the end of one year,
at each dose reduction, at each drug discontinuation, and at study
conclusion were calculated for the entire cohort and individually
for each of the three BMI categories. Simple and multiple linear
regression analysis were performed to identify the unadjusted and
adjusted association (adjusted for age, gender and ethnicity)
between percentage weight loss (centered at 5%) and the mean
percentage dose reductions of anti-diabetic medications (sulfonylureas, insulin, and all classes combined) for the total cohort. This
analysis was not included for sitagliptin, metformin, or individually
for the three BMI categories due to small numbers in these

Baseline data collection
Case records of the study participants were reviewed, and
demographic data (age, gender, race), cardiovascular risk factors
(smoking, diabetes, hypertension), medication history (anti-diabetic
medications, anti-hypertensive medications, anti-obesity medications, and lipid lowering drugs), clinical parameters (height,
weight, systolic and diastolic blood pressure) and laboratory
parameters {fasting glucose, HbA1C, total cholesterol, low density
lipoprotein cholesterol (LDL), high density lipoprotein cholesterol
(HDL), triglycerides} were collected. BMI was calculated as per
standard guidelines [10]. Metabolic syndrome was determined
using National Cholesterol Education program (NCEP ATP III)
guidelines [11]. Type-2 diabetes was identified by physician
diagnosis.

Patient follow-up and weight management intervention
details
Patients underwent team-based, comprehensive evaluation and
treatment for weight loss. On an average, study participants had
bimonthly clinic visits. Assessments consisted of physicianconducted medical history and physical examination, blood tests
(as described above), and detailed dietary, behavioral, and exercise
evaluations. Treatment was individualized, but consisted of a
calorie-restricted diet, typically utilizing meal replacements,
approximately 1000 kcal/day deficit, a behavior modification
plan, and a plan for increasing physical activity utilizing both
PLoS ONE | www.plosone.org
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individual groups, which resulted in the regression model being
unstable. Simple and multiple logistic regression analyses were
performed to identify the unadjusted and adjusted association
(adjusted for age, gender and ethnicity) between percentage weight
loss (centered at 5%) and discontinuation of anti-diabetic
medications (coded as categorical variables) for the total cohort.
This analysis was performed for insulin, sulfonylureas and all
classes combined, but not for sitagliptin, metformin and individual
BMI categories, for the same reason described above. P
value,0.05 was considered statistically significant. All analyses
were performed using Stata 11.0 statistical software.

Table 1. Baseline comparison between included patients
(study cohort) and excluded patients.

Results
Baseline characteristics
In total, 121 patient records (69 from Johns Hopkins and 52
from George Washington) were identified and reviewed. Of these,
50 patient records were excluded as they did not have a diagnosis
of diabetes. The remaining 71 patients had a diagnosis of diabetes.
Of these, 7 were excluded as they had less than 6 months follow-up
data. Four more were excluded due to physical limitations that
prevented adherence to the prescribed physical activity. 3 more
were excluded because, though they were diabetic and successfully
lost weight, they were unsuccessful in dose reductions of antidiabetic medications. 7 more were excluded because, though
diabetic, they neither lost weight nor were successful in reducing
anti-diabetic medications. Hence, of the 71 diabetic patients, 21
were excluded and the remaining 50 patients formed the final
study cohort.
In summary the final study cohort comprised of 50 patients (34
patients from Johns Hopkins and 16 from George Washington)
with diabetes at the time of enrollment into the study who had at
least one dose reduction or discontinuation of any of the antidiabetic medications during the follow-up period. The proportion
of smokers, patients with a diagnosis of hypertension, diabetes
mellitus and metabolic syndrome were significantly higher in the
study cohort when compared to the excluded patients (Table 1).
Further, the study cohort had a higher mean fasting glucose and a
higher mean HbA1c compared to the excluded patients (Table 1).
However, the excluded patients had significantly higher mean
LDL and total cholesterol compared to the study cohort (Table 1).
With regard to medications, significantly higher proportions of
participants in the study cohort took anti-diabetic, antihypertensive, anti-obesity, and lipid lowering drugs compared to excluded
patients (Table 1).
Baseline characteristics of the study cohort (study cohort and the
3 BMI categories) are listed in Table 2 and Table S1. The mean
age was 53.4612.7 years. Males formed 58% of the cohort. 66%
were Caucasian. Mean initial body weight was 136.5624.0 kgs ;
mean initial BMI was 35.164.7 kg/m2. When the three BMI
categories were compared at baseline, the morbidly obese had
significantly higher fasting glucose, total cholesterol, LDL
cholesterol, HbA1C and serum triglycerides compared to the
other two BMI categories (Table 2) (all P-values,0.05). Mean
HDL was significantly lower in the morbidly obese compared to
the other two BMI categories (Table 2). The proportion of patients
with hypertension and metabolic syndrome was also significantly
higher in the morbidly obese. The overweight and the obese did
not differ significantly with regard to baseline variables.

Excluded
patients

(n = 50)

(n = 71)

Age (yrs)

53.4612.7

51.7613.9

0.211

Males- n (%)

29 (58)

40 (56)

0.352

Caucasians – n (%)

33 (66)

43 (61)

0.106

African Americans – n (%)

17 (34)

28 (39)

0.113

*Current Smokers – n (%)

29 (58)

30 (42)

0.021

*Hypertension- n (%)

29 (58)

33 (46)

0.033

P-value

*Diabetes- n (%)

50 (100)

21 (30)

,0.001

*Metabolic syndrome–n (%)

26 (52)

30 (42)

0.031

Mean weight (Kgs)

136.5624.0

127.0638.1

0.126

Mean BMI (Kg/m2)

35.164.7

32.866.0

0.235

BMI # 30

13 (26)

18 (25)

0.331

BMI: 31–39

30 (60)

44 (62)

0.173

BMI categories- n (%)

BMI$40

7 (14)

9 (13)

0.236

Systolic BP (mmhg)

143613.2

148623.6

0.116

Diastolic BP (mmhg)

9169.37

89611.8

0.237

*Fasting glucose (mg/dl)

111658

92621

0.011

*HbA1c %

8.661.6

6.961.1

0.021

*Total cholesterol (mg/dl)

205646.4

252623.7

0.039

*Total cholesterol (mmol/l)

5.3061.2

6.5160.6

0.039

*LDL (mg/dl)

147659

163636

0.016

*LDL (mmol/l)

3.861.5

4.260.9

0.016

HDL (mg/dl)

45613

43613

0.317

HDL (mmol/l)

1.260.3

1.160.3

0.317

Triglycerides (mg/dl)

174647

169654

0.184

Triglycerides (mmol/l)

1.9860.50

1.9260.61

0.184

*Anti-diabetes drugs- n (%)

50 (100)

21 (30)

,0.001

*Metformin- n (dose/day)

30 (1.75 g)

13 (1 g)

0.012

*Sulphonylureas- n

39

7

,0.001

*Glyburide- n (dose/day)

6 (10 mg)

2 (10 mg)

,0.001

*Glipiside- n (dose/day)

10 (10 mg)

2 (10 mg)

,0.001

*Glymipride- n (dose/day)

23 (2–4 mg)

5 (2–4 mg)

,0.001

*Sitagliptin- n (dose/day)

21 (100 mg)

1 (100 mg)

,0.001

*Insulin- n (dose/day)

31 (15 U)

2 (15 U)

,0.001
,0.001

*Lipid Lowering drugs- n (%)

32 (64)

27 (38)

*Anti-HTN drugs- n (%)

29 (58)

33 (46)

0.039

*Anti-obesity drugs- n (%)

8 (16)

9 (13)

0.051

*indicate significant differences (P-value,0.05).
LDL: Low Density Lipoprotein Cholesterol,
HDL: High Density Lipoprotein Cholesterol,
HTN: Hypertension,
BMI: Body Mass Index (weight in kilograms/height in meters squared).
doi:10.1371/journal.pone.0032395.t001

of 12.762.1 kgs (14.263.2% of initial body weight). Mean weight
at study exit was 131.1621.7 kgs, for a mean weight reduction of
10.864.1 kgs (11.164.7% of initial body weight). The total
cohort, the overweight, the obese and the morbidly obese had
significantly (all P,0.05) lower weight, systolic blood pressure,

Participant characteristics at study exit (Table 3)
On average, we had follow-up data for 30.2612.9 months, and
1740 person-months of follow-up overall. Mean weight after 1
year of follow-up was 127.569.7 kgs, for a mean weight reduction
PLoS ONE | www.plosone.org
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Table 2. Baseline characteristics of the study patients according to BMI categories.

Variables

Entire cohort

BMI: 25–30

BMI: 31–39

BMI$40

(n = 50)

(n = 13)

(n = 30)

(n = 7)

P values

Age (yrs)

53.4612.7

52.5613.6

53.1616.4

53.4614.9

0.136

Males- n (%)

29 (58)

5 (38)

19 (63)

5 (71)

0.355

Caucasians – n (%)

33 (66)

8 (62)

21 (70)

4 (57)

0.512

African Americans – n (%)

17 (34)

5 (38)

9 (30)

3 (43)

0.217

Current Smokers – n (%)

29 (58)

3 (23)

21 (70)

5 (71)

0.245

*Hypertension- n (%)

29 (58)

4 (31)

19 (63)

6 (86)

0.021

*Metabolic syndrome–n (%)

26 (52)

3 (23)

18 (60)

5 (71)

0.036
0.013

*Mean weight (Kgs)

136.5624.0

122.1618.6

133.4616.8

142.4618.6

*Mean BMI (Kg/m2)

35.164.7

28.960.7

35.263.3

43.762.4

0.025

Systolic BP (mmhg)

143613.2

140616.9

145612.2

141613.44

0.122

Diastolic BP (mmhg)

9169.37

94610.77

90612.57

9369.47

0.135

*Fasting glucose (mg/dl)

111658

104622

116641

121659

0.031

*HbA1c %

8.661.6

8.461.9

8.761.4

9.161.7

0.022

*Total cholesterol (mg/dl)

205646.4

191637.7

201651.3

217671

0.031

*Total cholesterol (mmol/l)

5.361.2

4.961.0

5.261.3

5.661.8

0.031

*LDL (mg/dl)

147659

123643.2

145651.9

156670.7

0.010

*LDL (mmol/l)

3.861.5

3.261.1

3.761.3

4.061.8

0.010

*HDL (mg/dl)

45613

49611

45613.7

39611.2

0.033

*HDL (mmol/l)

1.260.3

1.360.3

1.260.3

1.060.3

0.033

*Triglycerides (mg/dl)

174647

156652

182667

188632.8

0.028

*Triglycerides (mmol/l)

4.561.2

4.061.3

4.761.7

4.960.8

0.028

Anti-diabetes drugs- n (%)

50 (100)

13 (100)

30 (100)

7 (100)

0.175

Metformin- n (dose/day)

30 (1.75 g)

8 (1 g)

15 (1.75 g)

7 (2 g)

0.452

Sulphonylureas- n

39

7

21

11

0.611

Glyburide- n (dose/day)

6 (10 mg)

1 (10 mg)

2 (10 mg)

3 (10 mg)

0.365

Glipiside- n (dose/day)

10 (10 mg)

2 (10 mg)

2 (10 mg)

6 (10 mg)

0.514

Glymipride- n (dose/day)

23 (2–4 mg)

4 (2–4 mg)

17 (2–4 mg)

2 (2–4 mg)

0.156

Sitagliptin- n (dose/day)

21 (100 mg)

2 (100 mg)

15 (100 mg)

4 (100 mg)

0.356

*Insulin- n (dose/day)

31 (15 U)

3(10 U)

23 (15 U)

5 (20 U)

0.041

Lipid Lowering drugs- n (%)

32 (64)

5 (38)

21 (70)

6 (86)

0.128

Anti-HTN drugs- n (%)

29 (58)

4 (31)

18 (60)

7 (100)

0.138

Anti-obesity drugs- n (%)

8 (16)

0 (0)

5 (17)

3 (43)

0.112

*indicate significant differences (P-value,0.05). All are between group comparisons.
LDL: Low Density Lipoprotein Cholesterol,
HDL: High Density Lipoprotein Cholesterol,
HTN: Hypertension,
BMI: Body Mass Index (weight in kilograms/height in meters squared).
Other medication details at baseline are provided in supplemental file.
doi:10.1371/journal.pone.0032395.t002

patients in our study (overweight, 13; obese, 30; morbidly obese,7),
30 used metformin (overweight, 8; obese, 15; morbidly obese, 7),
39 sulfonylureas (overweight, 9; obese, 24; morbidly obese, 7), 31
insulin (overweight, 3; obese, 23; morbidly obese, 5) and 21 used
sitagliptin (overweight, 2; obese, 15; morbidly obese, 4). The
average dose/day for these medications are detailed in Table 2.
The three BMI categories did not differ with respect to average
dose/day for these medications, except that morbidly obese
patients were receiving a higher dose of insulin compared to the
other two categories.
By study exit, 44% (22/50) of the study patients were successful
in discontinuing one or more of their anti-diabetic medications.

diastolic blood pressure, fasting glucose, HbA1C, total cholesterol,
LDL, and triglycerides compared to their baseline values (Tables 2
and 3). The overweight achieved greater mean weight loss, mean
fasting glucose, and mean HbA1C reduction when compared to
other BMI categories at study exit (Table 3). The morbidly obese
had a higher mean systolic blood pressure, diastolic blood
pressure, total cholesterol, LDL cholesterol and triglycerides
compared to the other two BMI categories at study exit
(Table 3). Mean HDL was lowest among patients in the morbidly
obese category at study exit.
Dose reduction or discontinuation of anti-diabetic
medications and weight loss. (Tables 2 and 4): Of the 50
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Table 3. Participant characteristics at study exit.

Entire cohort

BMI:25–30

BMI: 31 to 39

BMI$40

(n = 50)

(n = 13)

(n = 30)

(n = 7)

Mean period of follow-up (months)

30.2612.9

27.668.5

33.7611

1266.5

0.122

Person months of follow-up (months)

1740

403

1067

270

0.317

Variables

P values

* Weight after one year (Kgs)

127.569.6

100.266.4

119.369.9

138.367.3

0.017

*Weight reduction after 1 year (Kgs)

12.762.1

13.663.6

11.362.4

7.363.1

0.029

*% weight loss after 1 year

14.263.2

15.164.6

13.963.8

9.263.3

0.011

* Weight at study exit (Kgs)

131.1621.7

107612.7

127619.5

140.2626.8

0.031

*Weight reduction at study exit (Kgs)

10.864.1

11.365.1

9.964.0

4.964.9

0.017

*% weight loss at study exit

11.164.7

12.863.9

11.765.1

7.264.4

0.013

*HbA1C (%) at study exit

8.161.2

7.661.1

8.060.6

8.960.3

0.037

*Reduction in HbA1C (%) at study exit

0.560.3

0.960.45

0.660.27

0.260.9

0.033
0.012

*Systolic blood pressure (mmhg)

138619.1

136614.7

140615.2

147621.3

*Diastolic blood pressure (mmhg)

8668.5

8269.9

87610.1

9068.45

0.017

Fasting glucose (mg/dl)

103633

100614

108624

115631

0.166

*Total cholesterol (mg/dl)

198633.9

186623.5

192618.2

212673

0.021

*Total Cholesterol (mmol/l)

5.160.8

4.860.6

4.960.4

5.561.9

0.021
0.017

*LDL (mg/dl)

143628.9

116627.2

132626.8

151647.3

*LDL (mmol/l)

3.660.7

3.060.7

3.460.7

3.961.2

0.017

*HDL (mg/dl)

44611.8

49613.1

46611.2

3767.1

0.026

*HDL (mmol/l)

1.160.3

1.360.3

1.260.3

0.960.2

0.026

* Triglycerides (mg/dl)

167632.7

140638

167670

179641.7

0.016

* Triglycerides (mmol/l)

4.360.8

3.661.0

4.361.8

4.661.2

0.016

*indicate significant differences (P-value,0.05), all are between group comparisons.
LDL: Low Density Lipoprotein Cholesterol,
HDL: High Density Lipoprotein Cholesterol,
BMI: Body Mass Index (weight in kilograms/height in meters squared).
Study exit: developed primary outcome of interest or administratively censored at study conclusion in March 2011.
doi:10.1371/journal.pone.0032395.t003

respective medications. The mean percentage weight loss that was
associated with at least one dose reduction of sulfonylureas, insulin,
and sitagliptin were 5.1% (7.061.6 kgs), 4.3% (5.961.9 kgs) and
7.1% (9.762.1 kgs), respectively.

Mean weight loss associated with the discontinuation of one or
more of these medications was 15.365.8 kgs. However, 1 patient
was able to discontinue one of his anti-diabetic medications
(insulin) at a weight loss of just 3.6 kgs and one patient needed to
lose 28.6 kgs to discontinue one of his anti-diabetic medications
(insulin). Mean percentage weight loss associated with the
discontinuation of one or more of these medications was
11.263.5%.
Mean weight loss associated with at least one dose reduction was
7.763.8 kgs. At the extremes, one patient was successful in having
a dose reduction of his insulin after a weight loss of just 2.3 kgs,
while one patient had to lose 17.7 kgs to achieve an insulin dose
reduction. A mean 5.662.8% weight loss was associated with at
least one dose reduction.
When individual anti-diabetic medication classes were analyzed,
none of the patients discontinued or reduced the dose of
metformin, but 36% (14/39) of patients using sulfonylureas
discontinued this medication, 23% (7/31) of those using insulin
discontinued this medication, and 19% (4/21) of those using
sitagliptin discontinued this medication. The mean percentage
weight loss that was associated with discontinuing sulfonylureas,
insulin and sitagliptin were 14.0% (19.168.2 kgs), 11.4%
(15.665.5 kgs), and 7.1% (9.762.1 kgs), respectively.
With respect to dose reductions, 51% (20/39) of those using
sulfonylureas, 48% (15/31) of those using insulin and 19% (4/21)
of those using sitagliptin achieved at least one dose reduction of the
PLoS ONE | www.plosone.org

Association between percentage weight lost and
predicted percentage dose reduction of anti-diabetic
medications
For every 5% weight loss, on average, the dose of sulfonylureas,
insulin and any of the anti-diabetic medications was predicted to
be reduced by 39%, 42% and 49%, respectively (Table 5). Also,
for every 5% reduction in weight, the odds ratio of discontinuing
sulfonylureas, insulin and any of the anti-diabetic medications
were 1.24, 1.30 and 1.37, respectively (Table 6).

Discussion
It is well-demonstrated that lifestyle changes, such as decreased
caloric intake and increased physical activity leading to weight loss
can decrease the incidence and progression of DM [9,14,15]. In this
study, we examined the magnitude of weight loss associated with the
reduction of dose or discontinuation of anti-diabetic medications in
a selected sample of patients with DM who attended 2 Universitybased weight management centers. While a number of previous
studies suggest that weight loss often leads to diminished need for
anti-diabetic medications [16,17] we are not aware of any previous
5
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Table 4. Weight loss and details of anti-diabetes drug dose reduction/discontinuation.

Variables

Entire cohort

BMI:25–30

BMI: 31–40

BMI$41

(n = 50)

(n = 13)

(n = 30)

(n = 7)

No. using anti-diabetic medications initially

50

13

30

7

n (%)" discontinued anti-DM medication

22 (44)

5 (38)

14 (47)

3 (43)

% weight loss at any anti-DM discontinuation

11.263.5

8.962.4

11.363.1

14.162.1

n (%)" who had at least one dose reduction

50 (100)

13 (100)

30 (100)

7 (100)

% weight lost at first dose reduction

5.662.8

3.862.1

5.662.3

4.962.8

No. of dose reductions of any anti-DM

54

29

20

5

No. using Metformin at study initiation

30

8

15

7

No. who discontinued Metformin

0

0

0

0

No. with one dose reduction of Metformin

0

0

0

0

No. using SU at study initiation

39

7

21

11

n (%)" who discontinued SU

14 (36)

4 (57)

10 (48)

0 (0)

No. who discontinued glypiside

3

2

1

0

Time to discontinuing SU (months)

15.266.5

9.763.1

16.267.2

-

% weight lost at SU discontinuation

1464.5

963.2

1667.8

-

n (%)" with one dose reduction of SU

20 (51)

5 (71)

15 (71)

-

Time to first dose reduction of SU (months)

7.161.9

5.261.1

7.162.4

-

No. of dose reductions of SU

42

13

29

-

% weight loss at first dose reduction of SU

5.161.2

4.261.7

5.461.8

-

No. using Glyburide at study initiation

6

1

2

3

No. who discontinued glyburide

2

1

1

0

No. using Glymipride at study initiation

23

4

17

2

No. who discontinued glymipride

9

2

7

0

No using glypiside at study initiation

10

2

2

6

No. using Insulin at study initiation

31

3

23

5

n (%)" who discontinued insulin

7 (23)

2 (67)

4 (17)

-

% weight lost at Insulin discontinuation

11.461.5

10.161.8

11.361.2

-

Time to discontinuing insulin (months)

14.566.8

11.163.8

15.868.1

-

n (%)" with at least one insulin dose reduction

15 (48)

3 (100)

14 (61)

2 (40)

Time to first dose reduction of Insulin

4.561.2

3.860.9

4.661.6

6.1

% weight loss at first dose reduction of Insulin

4.361.5

3.161.3

4.761.1

5.1

No. of dose reductions of Insulin

24

16

39

4

No. using SGT at study initiation

21

2

15

4

n (%)" who quit SGT

4 (19)

1 (50)

2 (13)

1 (25)

% weight lost at SGT discontinuation

7.162.1

7.261.9

6.862.3

7.5

Time to discontinuing SGT

1663.1

16.162.5

15.562.1

17

n(%)" with at least one dose reduction of SGT

4 (19)

1 (50)

2 (13)

1 (25)

Time to first dose reduction of SGT

1663.1

16.162.5

15.562.1

17

% weight loss at first dose reduction of SGT

7.162.1

7.261.9

6.862.3

7.5

No. of dose reductions of SGT

1

1

1

1

No. who quit both Insulin and SU

3

1

2

0

Anti-DM: anti-diabetes medications.
SU: Sulphonylureas, SGT: Sitagliptin,
BMI: Body Mass Index (weight in kilograms/height in meters squared).
"
: % mentioned are with respect to the total number in each group who were using that particular drug at study initiation.
doi:10.1371/journal.pone.0032395.t004

study that aimed to quantify the magnitude of weight loss associated
with an improvement in blood sugars sufficient to warrant a
decrease in dose, or discontinuation of anti-diabetes medications.
Though trials like Look AHEAD have analyzed the economic

PLoS ONE | www.plosone.org

impact of anti-diabetic drug dose reductions consequent to weight
loss [16], our observational study appears to be the first to identify
the association between the magnitude of the weight loss and dose
reductions or discontinuations of anti-diabetic medications.
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prompted the treating physicians to discontinue insulin earlier
than sulfonylureas. Also, we observed that none of the patients in
our cohort discontinued metformin or had even a single dose
reduction. The reason for this is likely that the treating physicians
preferred retaining metformin for its weight-reducing and insulin
resistance-decreasing properties, rather than for its effect on
glycemia [18]. In additional, because there is minimal risk of
hypoglycemic effects with metformin, compared with insulin or
sulfonylureas, less aggressive discontinuation of metformin may be
preferred.
Also, it is encouraging to note that 3 of the 4 different classes of
anti-diabetic medications used in our study could be dose
reduced/discontinued with weight loss. Hence it should be
emphasized that, irrespective of the type of anti-diabetic
medication and its mechanism of action, weight loss indeed helps
in dose reduction/discontinuation and hence should be uniformly
prescribed to overweight and obese patients with type-2 diabetes
mellitus.
Our observation that 50 patients (study cohort) who could lose
weight were also successful in dose reductions/discontinuation of
anti-diabetic medications while only 3 who lost weight were
unsuccessful in dose reductions/discontinuation of anti-diabetic
medications is encouraging.
Our study participants in the morbidly obese category showed
some interesting differences. They tended to have poorer
cardiovascular risk profiles at baseline, and achieved lesser
reduction of body weight, blood pressure, and lipid levels
(Tables 1, 2 and 3). Also, while some had dose reductions, none
was successful in discontinuing any of their anti-diabetes
medications. The possible reason for this observation could be
that the participants in the morbidly obese category had a higher
HbA1c% at baseline (Table 2). Though they did achieve
significant reduction in their HbA1c% at study exit (Table 3) this
may not have been sufficient to translate into discontinuation of
any of the anti-diabetic medications. Hence, it may be reasonable
to hypothesize that greater magnitudes of weight loss may be
required for the participants in this group to discontinue antidiabetic medications when compared to the participants in the
other BMI categories.
Evidence from observational studies and clinical trials has
clearly shown that morbidly obese patients with type 2 DM benefit
from bariatric surgery [19,20,21]. Nearly 50–80% of these patients

Table 5. Linear regression analysis associating percentage
weight loss (every 5%) and mean % dose reductions of antidiabetes medications (entire cohort).

Anti-diabetes medications

Mean % dose reductions
Mean %

95% C.I

P-value

Unadjusted

45

13–65

0.023

*Adjusted

39

18–71

0.039

Unadjusted

51

11–69

0.041

*Adjusted

42

14–64

0.044

Unadjusted

58

18–73

0.027

*Adjusted

49

31–70

0.031

Sulphonylureas

Insulin

Any anti-DM medications

*adjusted for age, gender and ethnicity.
Anti-DM: antidiabetic.
doi:10.1371/journal.pone.0032395.t005

This retrospective cohort study found that the selected patients
achieved 14.2% mean weight loss at one year, and 11.1% at study
conclusion (30.2 months mean follow-up), respectively (Table 2).
The high magnitude of weight loss is not necessarily surprising
given that this sample was selected to identify those patients who
were successful enough in their lifestyle changes to be able to lower
the dose or discontinue at least one anti-diabetic medication.
Further, by virtue of being enrolled in a University-based,
comprehensive weight management center program, they each
had access to an intensive, multi-specialist support team that
utilized state-of-the-art weight management tools and techniques.
44% of these patients with type 2 diabetes successfully discontinued one or more of their anti-diabetes medications. On average,
11.2% of initial body weight loss was required to achieve this
(Table 3).
We observed that the percentage weight loss that was associated
with discontinuing or reducing the dose of insulin was lower than
that for sulfonylureas. The fact that insulin is shorter acting than
sulfonylureas, and that insulin involves injections, may have

Table 6. Logistic regression analysis associating percentage weight loss (every 5%) and discontinuation of anti-diabetes
medications (entire cohort).

Anti-diabetes medications

Discontinuation of anti-diabetes medications
Odds ratio

95% C.I

P-value

Unadjusted

1.31

1.04–1.55

0.041

*Adjusted

1.24

1.01–1.49

0.045

Unadjusted

1.39

1.07–1.63

0.039

*Adjusted

1.30

1.04–1.57

0.042

Unadjusted

1.49

1.08–1.70

0.033

*Adjusted

1.37

1.12–1.72

0.042

Sulphonylureas

Insulin

Any anti-DM medications

*adjusted for age, gender and ethnicity.
Anti-DM: antidiabetic.
doi:10.1371/journal.pone.0032395.t006
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achieved complete remission of diabetes. When followed,
prevalence of diabetes decreased at 2 years, 8 years and even
after 10 years after surgical intervention in these patients [20].
Further, bariatric surgery provided sustained improvement in
quality of life and significantly reduced mortality [21]. At the end
of 2 years, in a clinical trial setting, surgically treated patients had
lost 20% of their body weight and reduced their HbA1c% by 2.5
[20]. However, in our study, morbidly obese patients lost a lesser
amount, 7.2% of their body weight, and reduced HbA1c% by 0.2
by study exit (Table 3). In addition to reduction in insulin
resistance, bariatric surgery is known to increase incretins like
glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which lead to improved beta-cell
function [21]. This may help explain the dramatic and sustained
response that bariatric surgery can achieve in the morbidly obese
when compared to average results using medical management.
Diabetes management has moved from a guidelines-based
approach to an individualized approach that takes factors such
as age, comorbidities, diabetes-associated complications, symptoms and patient satisfaction into account in deciding on treatment
choices and doses [22]. In a recent review by Ismail-Beigi et al.,
the authors described the superiority of individualized diabetes
management over guideline-based diabetes management after
pooling multiple trial data [22]. Consistent with this novel
approach, our study, which was based on individualized and
comprehensive management of obese diabetic patients, took the
overall clinical profile of the patient, rather than any single factor
into making treatment choices. Hence, the results of our study may
be applicable to any physician-supervised, outpatient weight
management approach. It is encouraging that success at
decreasing and discontinuing anti-diabetic medications was
achieved with relatively modest weight loss, and that even a
medication with a very substantial impact on patient healthrelated quality of life - insulin [23] - was discontinued at levels of
weight loss that can often be achieved in physician-guided settings.
Small sample size is an important limitation of our study that
decreased the precision of our estimates and prevented us from
examining effect modification attributable to gender, race and BMI

categories. The retrospective cohort design limits our data to whatever
is recorded in patient case records. The convenience sampling strategy,
including only those obese patients with diabetes who successfully
achieved at least one dose reduction of their anti-diabetic medications
may have introduced a selection bias, by selecting individuals who were
well motivated or consistent in their attendance at follow-up visits, and
thus may not be representative of all clinic attendees, or all patients with
type-2 diabetes. Missing data was another limitation. Though we used
statistical adjustments, it is still possible that the estimates might have
been biased due to these missing data. Also, it would have been
interesting to compare our study cohort with patients who had
significant weight loss but were unsuccessful in dose reductions/
discontinuation of anti-diabetic medications. We were unable to do this
analysis as we had only 3 patients in this category.
In conclusion, among the obese patients with type 2 diabetes
studied, intentional weight loss of a mean magnitude of 7–14%
was typically required for full discontinuation of at least one antidiabetic medication. Discontinuation of insulin was achieved at a
mean weight reduction of 11% of starting body weight. Successful
reduction in dosage of anti-diabetes medications was typically
achieved with a lesser, 4–7% weight loss. Also, with just 5% weight
loss, doses of sulphonylureas, insulin and any of the anti-diabetic
medications could be reduced by 39%, 42% and 49% respectively.
Knowledge of the modest magnitude of weight loss typically
required to successfully reduce medication use among overweight
and obese patients with type 2 diabetes may be helpful to health
care providers and patients alike.
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